Zacks Investment Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-20,146
Closed -$1.28M 732
2025
Q1
$1.28M Buy
20,146
+703
+4% +$47.8K 0.01% 379
2024
Q4
$1.52M Buy
19,443
+2,522
+15% +$203K 0.01% 369
2024
Q3
$1.36M Buy
16,921
+1,740
+11% +$141K 0.01% 381
2024
Q2
$1.26M Buy
15,181
+1,473
+11% +$130K 0.01% 343
2024
Q1
$1.17M Buy
13,708
+2,884
+27% +$226K 0.01% 385
2023
Q4
$926K Sell
10,824
-1,102
-9% -$95.3K 0.01% 386
2023
Q3
$1.07M Buy
11,926
+993
+9% +$88.7K 0.01% 364
2023
Q2
$931K Buy
+10,933
New +$924K 0.01% 384
2020
Q4
Sell
-7,154
Closed -$624K 544
2020
Q3
$624K Sell
7,154
-5,740
-45% -$502K 0.01% 379
2020
Q2
$1.16M Sell
12,894
-1,668
-11% -$168K 0.03% 278
2020
Q1
$1.45M Sell
14,562
-670
-4% -$72.7K 0.04% 242
2019
Q4
$1.75M Sell
15,232
-2,663
-15% -$322K 0.03% 296
2019
Q3
$2.26M Buy
17,895
+7,906
+79% +$1M 0.05% 234
2019
Q2
$1.2M Buy
+9,989
New +$983K 0.02% 373
2014
Q1
Sell
-13,246
Closed -$558K 713
2013
Q4
$558K Sell
13,246
-7,514
-36% -$309K 0.02% 347
2013
Q3
$828K Buy
20,760
+1,088
+6% +$45.6K 0.04% 249
2013
Q2
$813K Buy
+19,672
New +$796K 0.04% 247

Other funds holding HAE

Zacks Investment Management's HAE Position: Q2 2025 in Review

Zacks Investment Management sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 20,146 shares — an estimated $1.28M sold.

Zacks Investment Management first reported a position in HAE in Q2 2013 and held it in 17 quarters. The position peaked at $2.26M in Q3 2019. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Zacks Investment Management reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
  • Zacks Investment Management sold 20,146 Haemonetics shares in Q2 2025, an estimated $1.28M.
  • Zacks Investment Management first reported a position in Haemonetics in Q2 2013 and held it in 17 quarters.
  • Zacks Investment Management's Haemonetics position peaked at $2.26M in Q3 2019.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Zacks Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.